TriSalus Life Sciences (TLSI) Depreciation & Amortization (CF) (2022 - 2026)

TriSalus Life Sciences' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $135000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 21.51% year-over-year to $135000.0 in Q1 2026; TTM through Mar 2026 was $589000.0, a 20.51% decrease from a year earlier, with the FY2025 full-year figure at $626000.0, down 15.86% from the prior year.
• Depreciation & Amortization (CF) rose to $135000.0 in Q1 2026 per TLSI's latest filing, from $126000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $194000.0 in Q4 2023 and bottomed at -$54000.0 in Q4 2022.
• The 5-year median for Depreciation & Amortization (CF) is $168500.0 (2025), against an average of $152500.0.
• Across the five-year window, Depreciation & Amortization (CF) jumped 459.26% in 2023 and tumbled 34.72% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at -$54000.0 in 2022, then soared by 459.26% to $194000.0 in 2023, then decreased by 0.52% to $193000.0 in 2024, then tumbled by 34.72% to $126000.0 in 2025, then rose by 7.14% to $135000.0 in 2026.
• Per Business Quant, the three latest TLSI Depreciation & Amortization (CF) figures stand at $135000.0 (Q1 2026), $126000.0 (Q4 2025), and $163000.0 (Q3 2025).